Medicaid Spending on Drugs Marketed Without US Food and Drug Administration Approval in 2020

Simon J Gunter; Aaron S Kesselheim; Benjamin N Rome

doi:10.1001/jamainternmed.2021.7614

Medicaid Spending on Drugs Marketed Without US Food and Drug Administration Approval in 2020

JAMA Intern Med. 2022 Mar 1;182(3):342-345. doi: 10.1001/jamainternmed.2021.7614.

Authors

Simon J Gunter^{1

2}, Aaron S Kesselheim^{1

2}, Benjamin N Rome^{1

2}

Affiliations

¹ Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
² Harvard Medical School, Boston, Massachusetts.

Abstract

This cross-sectional study examines the proportion of Medicaid prescription and spending on drugs marketed in the United States without Food and Drug Administration approval.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Drug Approval*
Drug Costs
Drugs, Generic
Humans
Medicaid*
Pharmaceutical Preparations
United States
United States Food and Drug Administration

Substances

Drugs, Generic
Pharmaceutical Preparations